3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
37
Breast Neoplasms
26
Prostatic Neoplasms
22
Stomach Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
12
Lung Neoplasms
11
Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Interventions
enzalutamide
4
Docetaxel
2
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
abiraterone
1
Prednisone
1
PF06821497
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
Docetaxel
×
Clear all
NCT07287150
2026-05-06
InavoPC
Hoffmann-La Roche
Phase 2
Recruiting
100 enrolled
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled